(Q46348584)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23359179%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

title

Phase II trial of sequential subcutaneous interleukin-2 plus interferon alpha followed by sorafenib in renal cell carcinoma (RCC) (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23359179%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

main subject

phase II clinical trial

0 references

1 reference

José Luis Pérez-Gracia

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23359179%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Enrique Gallardo

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23359179%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

author name string

J P Maroto

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23359179%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

X G del Muro

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23359179%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

B Mellado

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23359179%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

R Andrés

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23359179%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

J Cruz

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23359179%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

M Domenech

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23359179%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

J A Arranz

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23359179%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

J A Meana

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23359179%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

publication date

29 January 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23359179%20AND%20SRC:MED&resulttype=core&format=json

Clinical and Translational Oncology

22 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23359179%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

volume

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23359179%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

issue

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23359179%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

page(s)

698-704

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23359179%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s12094-012-0991-z

22 February 2020

exact match

0 references

cites work

Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0991-Z

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0991-Z

Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0991-Z

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0991-Z

Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0991-Z

Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0991-Z

Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0991-Z

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0991-Z

Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0991-Z

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0991-Z

Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma: a phase II study of the Southwest Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0991-Z

Sorafenib with interleukin-2 vs sorafenib alone in metastatic renal cell carcinoma: the ROSORC trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0991-Z

Medroxyprogesterone, interferon alfa-2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis: results of a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0991-Z

Sorafenib in advanced clear-cell renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0991-Z

The current role of immunotherapy for renal cell carcinoma in the era of targeted therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0991-Z

Immunotherapy in renal cell carcinoma

21 January 2018

1 reference

12 December 2020

Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial

1 reference

12 December 2020

Sorafenib and pegylated interferon-α2b in advanced metastatic melanoma: a multicenter phase II DeCOG trial

1 reference

12 December 2020

Third-line sunitinib following sequential use of cytokine therapy and sorafenib in Japanese patients with metastatic renal cell carcinoma

1 reference

12 December 2020

Long-term follow-up of patients with metastatic renal cell carcinoma treated with intravenous recombinant interleukin-2 in Europe

1 reference

12 December 2020

Immunotherapy for advanced renal cell cancer

1 reference

12 December 2020

10.1007/S12094-012-0991-Z

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23359179%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

1 reference